Dual PPAR α/γ Agonists: Continuing Cardiac Concerns

Sir,

PPARs are nuclear receptors that promoted fatty acid metabolism. PPAR α agonists (like fibrates) lower triglyceride and increase HDL levels. PPAR γ agonists (like thiazolidinediones) reduce blood glucose. Dual α/γ PPAR agonist have the dual promise of reducing both blood glucose and triglycerides and increasing HDL. Saroglitazar is the only dual α/γ PPAR agonist available in India. The drug also holds the distinction of being an ‘Indian’ drug and is extensively marketed. However, it wasn’t the first drug to act on both PPAR receptors - its closely related molecules were tried in the past and were dropped because of cardiac toxicity. Muraglitazar, developed by Bristol Myers Squibb, was the first drug to reach phase III clinical trials in this class. Nissen et al.,[1] in an RCT concluded that until and unless the safety of muraglitazar was established in a dedicated CVOT, it should not be approved for clinical use in diabetes based on lab end points alone. Tesaglitazar, another drug in the same class, was found to have renal (reduced glomerular filtration rate) and cardiac adverse effects and Astra zeneca, its developer, pulled the plug on further development. Aleglitazar developed by Roche, also met with the same fate. Several other glitazars (navaglitazar, ragaglitazar, farglitazar, chiglitazar) also went to their early graves.[2] Given the failure of the three drugs in this class, the natural questions that arise are, is this increased MACE a class effect or a molecule specific effect? If we consider it a molecule specific effect, how different is saroglitazar (available in Indian market) from muraglitazar/aloglitazar/tezaglitazar on a structural level to believe that it will be different? Finally, do we have a reassuring CVOT to allay the fears, given the chequered history of this molecule’s ancestors?

These questions do not have easy answers.

Cardiovascular Safety of Diabetes Drugs

The CVOT is a particularly important safety valve, which FDA built into its approval pathway, ensuring that all anti diabetic drugs have to clear the bar of cardiovascular safety, before they reach the market. Given the cracks in post marketing surveillance, such safety precautions are well founded, even if they come at a higher upfront cost. There is currently no consensus on the duration of CVOTs - since most CVOTs are event driven and take large number of patients.

Figure 1 shows the duration of CVOTs in diabetes published so far.

Figure 2 shows the sample size of published CVOTS (compared with PRESS -VI for saroglitazar).

In contrast, the PRESS-VI trial 3 which used saroglitazar has a duration of just 12 weeks with a sample size of 300. The DCGI does not require CVOTs, nor is there is a minimum duration of trial required to ascertain safety. This loophole potentially leaves Indian patients vulnerable to drug-induced adverse effects.

Dual α/γ PPAR/Agonists-Mechanism of Cardiac Dysfunction

The molecular mechanism of cardiac dysfunction induced by glitazars remained obscure. A recent study in mice treated with tezaglitazar throws light on the mechanism.[3] The action of dual PPAR α/γ agonists requires activation of PPAR γ co-activator- 1 (PGC-1). This is a common coactivator for both PPARs and it regulates cardiac fatty acid oxidation, mitochondrial biogenesis and respiration. SIRT1 (sirtuin 1) expression serves as an additional lever of control and regulates PGC-1 expression by acetylation.

A direction reduction in PGC-1, or its deactivation by reduced SIRT1 expression will result in reduction in cardiac mitochondrial number. Glitazars cause competition between PPAR α and γ for PGC-1 and also reduce SIRT1 expression, thereby reducing cardiac mitochondrial abundance. This explains why inspite of being dual agonists, the final effect of glitazars is less than the sum of PPAR α and γ activation.
Interestingly, this reduced SIRT1 expression was ameliorated by resveratrol (found in grapes). Whether the use of resveratrol to reduce cardiac adverse effects of glitazars will work in humans, remains to be seen. Till date, there have been no human studies that have looked at (fibrates + thiazolidinediones) versus glitazars.

**Conclusion**

Following its initial use in diabetes with dyslipidemia (Triglyceride >200), saroglitazar has been studied for use in prediabetes and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NASH). Unlike other antidiabetic drugs, saroglitazar has not been tested in high risk patients enrolled in event driven cardiovascular outcome trials. Due to different regulatory requirements in India and its role that straddles two classes of drugs - antidiabetic and lipid lowering - saroglitazar continues to be used in India for various indications. Given the dismal history of its related molecules, its weaker evidence base and the molecular basis of cardiac dysfunction, endocrinologists should exercise caution in using these drugs, especially in those with higher cardiovascular risk.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**Karthik Balachandran**

Department of Endocrinology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, India

**Address for correspondence:** Dr. Karthik Balachandran, Department of Endocrinology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, India. E-mail: karthik2k2@outlook.com

**References**

1. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6.
2. Conlon D. Goodbye glitazars? Br J Diabetes Vasc Dis 2006;6:135-7.
3. Kallioura C, Kyriazis ID, Oka S, Lieu MJ, Yue Y, Area-Gomez E, et al. Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction. JCI Insight 2019;4:e129556.
4. Bhosle D, Bhosle V, Bobde J, Bhagat A, Shaikh H, Kadam R. Study of saroglitazar in treatment of pre-diabetes with dyslipidemia: STOP-D. J Assoc Physicians India 2018;66:14-7.
5. Jain MR, Giri SR, Bhoi B, Trivedi C, Rath A, Rathod R, et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int 2018;38:1084-94.
6. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017;66:180-90.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**Access this article online**

Quick Response Code: [QR Code Image]

Website: [www.ijem.in](http://www.ijem.in)

DOI: 10.4103/ijem.IJEM_542_19

**How to cite this article:** Balachandran K. Dual PPAR α/γ agonists: Continuing cardiac concerns. Indian J Endocr Metab 2019;23:586-7.

© 2019 Indian Journal of Endocrinology and Metabolism | Published by Wolters Kluwer - Medknow